Effects Of Ranibizumab On Corneal Neovascularization And Recurrent Vessels

Background:Corneal neovascularization not only brings nutrients to the cornea but also brings a large number of inflammatory cells and inflammatory factors to it.If we don't treat in time,it may eventually lead to a profound decline in vision.Infection,chronic hypoxia,chemical damage,physical trauma,and lack of limbal stem cells can cause corneal neovascularization.In the process of corneal neovascularization,we found that after the new blood vessels have subsided,the vessels grow into the cornea when the cornea contact risk factors again.At this time,it will be very hard to treat.Revascularization occurs in many fundus diseases and systemic diseases,which seriously affect the treatments.Vascular endothelial growth factor A(VEGF-A)plays a large role in angiogenesis,and these factors participate in vascular permeability and angiogenesis.Ranibizumab is a human VEGF-A antigen-binding fragment that can bind to all active isoforms of VEGF-A.Therefore,it is considered to be a non-selective VEGF-A inhibitor with strong anti-angiogenesis benefits.Purpose:We use mouse corneal suture model to induce corneal neovascularization and revascularization to study the therapeutic effect of ranibizumab.Ranibizumab as an anti-neovascular drug to treat corneal neovascularization at different times.Methods:Eighteen male C57 BL / 6J mice were randomly divided into 6 groups.Each group with 3 mice.We use corneal suture model.The sutures were removed on the 7th day after surgery,and the corneal sutures were placed again in the same place on the 37 th day.The left eye was selected as the surgical eye.Group A(ranibizumab group on days 0 and 37): ranibizumab 0.01 ml was given on the day of modeling,and tobramycin eye ointment was given to the eyes once a day after operation.Group B(ranibizumab group on day 3): On the 3rd day after modeling,ranibizumab was given,and tobramycin eye ointment was given once a day after surgery.Group C(the positive control group): Tobramycin dexamethasone eye ointment once a day after modeling.Group D(model group): Tobramycin eye ointment once a day after modeling.Group E(ranibizumab on day 37): Tobramycin eye ointment was given once a day after the first modeling,and 0.01 ml of ranibizumab was given on the day after the second modeling.Tobramycin eye ointment once a day after modeling.Group F(blank control group): no treatment.On the 3rd,7th,37 th,and 40 th days after operation,a slit lamp microscope anterior segment camera system was used to photograph the mice's corneas to record the corneal neovascularization and revascularization.In the first stage of the experiment,observe whether there is a difference in the length and area of corneal neovascularization on the 3rd and 7th days between groups A,B,C,D,E,and F.In the second stage of the experiment,observe whether there is a difference in the length and area of corneal revascularization on the 40 th day between groups A,C,D,E,and F.Result:The mouse corneal suture model was established to observe the therapeutic effect of the drug treat corneal neovascularization and the effect of the drug on revascularized treatment.Through the first stage of this experiment,we found that ranibizumab has a significant inhibitory effect on corneal neovascularization.Both ranibizumab and dexamethasone have better anti-angiogenesis effects than the model group.On the third day of the experiment,there was a significant difference in the length and area of corneal neovascularization between group A,group B,group C,group D and group E(P <0.05).The area of corneal neovascular between group A and C have no significantly different(P <0.05).There was no difference between groups B,D,and E.Group A,B,C,D,E have difference with group F in corneal length and area(P <0.05).On the seventh day of the experiment,there was a statistically significant difference in the length and area of neovascularization between group A and group B(P <0.05).There was a significant difference between group A and group C(P <0.05).The length and area of corneal neovascular in groups A is less than group B,C and D(P <0.05),and there is no difference between group B and group C.The differences between group A,B,C,D and E were statistically significant with group F(P <0.05).On the 40 th day of the experiment,there was a statistical difference in the length and area of revascularization between group A and C(P <0.05),and a significant difference in the length and area of revascularization between group A and D(P <0.05).There was a statistical difference in blood vessel area between group C and group D(P <0.05).There was no significant difference in the length and area of recurrent blood vessels between group A and group E(P> 0.05).Groups A,C,D,E have a statistically significant with group F(P <0.05).Conclusion:Both ranibizumab and dexamethasone can inhibit corneal neovascularization.Ranibizumab has a stronger inhibitory effect on corneal neovascularization than dexamethasone.In an early administration of ranibizumab has a stronger inhibitory effect on corneal neovascularization;Dexamethasone cannot inhibit recurrent corneal blood vessels while ranibizumab has an inhibitory effect on it.